Entrada Therapeutics, Inc. (TRDA) Tops Q2 EPS by $1.19

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q2 EPS of $1.55, $1.19 better than the analyst estimate of $0.36. Revenue for the quarter came in at $94.7 million versus the consensus estimate of $51.86 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Gordon Haskett cuts TJX Companies rating to Accumulate
• Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline